170105-16-5 Usage
Description
Imidafenacin, an M3/M1 muscarinic receptor antagonist, was introduced in
Japan for the oral treatment of OAB. The majority of OAB symptoms are
thought to result from overactivity of the detrusor muscle, which is primarily
mediated by acetylcholine-induced stimulation of muscarinic M3 receptors in the
bladder. Previously marketed muscarinic antagonists for OAB include propiverine,
tolterodine, oxybutynin, trospium, darifenacin, and solifenacin. In vitro,
imidafenacin is equally active against M1 and M3 receptors (Kb＝0.32 and
0.55nM, respectively), and approximately 10-fold less active against M2 receptors
(Kb＝4.13nM). Imidafenacin is chemically synthesized in three steps starting with alkylation of diphenylacetonitrile with dibromoethane, followed by condensation with 2-methylimidazole, and hydrolysis of the cyano group to a carboxamide group with 70% sulfuric acid.
Chemical Properties
White Solid
Originator
Kyorin (Japan)
Uses
Different sources of media describe the Uses of 170105-16-5 differently. You can refer to the following data:
1. A novel therapeutic agent for overactive bladder with antimuscarinic activity, on mediator release from urothelium and detrusor overactivity induced by cerebral infarction. A muscarinic antagonist.
2. Imidafenacin-d10 is deutirium labelled imidafenacin which is a novel therapeutic agent for overactive bladder with antimuscarinic activity, on mediator release from urothelium and detrusor overactivity induced by cerebral infarction.
Brand name
Staybla
Synthesis
Diphenylacetonitrile
(53) was alkylated with dibromoethane in the presence
of NaNH2 in toluene to give bromide compound 54. The bromide 54 was condensed with 2-methylimidazole
in the presence of Et3N in hot DMF to afford 2-methylimidazole
derivative 55. Hydrolysis of the cyano group of 55
with 70% sulfuric acid provided imidafenacin (VII).
Check Digit Verification of cas no
The CAS Registry Mumber 170105-16-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,0,1,0 and 5 respectively; the second part has 2 digits, 1 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 170105-16:
(8*1)+(7*7)+(6*0)+(5*1)+(4*0)+(3*5)+(2*1)+(1*6)=85
85 % 10 = 5
So 170105-16-5 is a valid CAS Registry Number.
InChI:InChI=1/C20H21N3O/c1-16-22-13-15-23(16)14-12-20(19(21)24,17-8-4-2-5-9-17)18-10-6-3-7-11-18/h2-11,13,15H,12,14H2,1H3,(H2,21,24)
170105-16-5Relevant articles and documents
4-(2-METHYL-1H-IMIDAZOL-1-YL)-2,2-DIPHENYLBUTANENITRILE SOLID FORM
-
Page/Page column 24, (2016/09/26)
The present invention relates to a solid form of 4-(2-methyl-1 H-imidazol-1-yl)-2,2- diphenylbutanenitrile phosphate intermediate and its use for preparing imidafenacin, and an improved process for preparing 4-(2-methyl-1-imidazolyl)-2,2- diphenylbutanamide, also known as imidafenacin, in good yield and purity using said solid form.
Preparation technology for imidafenacin
-
, (2016/11/24)
The invention discloses a preparation technology for imidafenacin and belongs to the pharmaceutical chemistry field. The method is as follows: 2-halogenated ethyl diphenylacetonitrile and 2-methyl imidazole are employed as initial raw materials, alcohol compounds are employed as a solvent, polyethylene glycol is employed as a phase-transfer catalyst, replacement and hydrolysis reactions are combined in an alkali metal hydroxide condition, and imidafenacin is prepared through one step. The technology is advantageous in that reaction steps are reduced, dosage of 2-methyl imidazole and the reaction temperature are lowered substantially, the reaction time is shortened, the synthesis yield is raised obviously, and the preparation technology is suitable for industrial production.
PROCESS FOR PRODUCING MUSCARINE RECEPTOR ANTAGONIST AND INTERMEDIATE THEREFOR
-
Page/Page column 6, (2008/06/13)
The industrial production of 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutanamide, a urinary incontinence remedy, necessitates elimination of problems concerning the use of a synthetic adsorbent, e.g., HP-20, the efficiency of operation with the same, purification efficiency, etc. An acid salt, e.g., hydrochloride or phosphate, of 4-(2-methyl-1-imidazolyl)-2,2- diphenylbutanamide or a hydrate of any of these salts is used as an intermediate. This intermediate is neutralized and then purified. Thus, high-purity 4-(2-methyl -1-imidazolyl)-2,2-diphenylbutanamide is easily obtained in satisfactory yield. The industrial-scale production process has been thus established.
